Merck & Co., Inc. with ticker code (MRK) have now 26 confirmed analysts covering the stock with the consensus suggesting a rating of ‘buy’. The range between the high target price and low target price is between $140.00 and $103.00 suggesting an average analyst share price target price of $124.44. (at the time of writing). Now with the previous closing price of $114.77 and the analysts are correct then there would likely be a percentage uptick in value of 8.4%. The 50 day MA is $104.69 and the 200 moving average now moves to $108.32. The company has a market capitalization of 296.51B. The current share price for the company is: $117.01 USD
The potential market cap would be $321,487,931,180 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of 63.59, revenue per share of $23.38 and a 5.4% return on assets.
Merck & Co., Inc. is a global healthcare company. The Company offers health solutions through its prescription medicines, including biological therapies, vaccines and animal health products. It operates through two segments: Pharmaceutical and Animal Health. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. Its human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed healthcare providers, such as health maintenance organizations. The Animal Health segment develops, manufactures and markets a range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services for the prevention, treatment and control of disease in all major livestock and companion animal species.
